CD274 and breast cancer: Indeed, promising clinical responses of metaplastic breast cancer to dual checkpoint blockade in the treatment-refractory setting have been observed, as well as high prevalence of programmed death ligand 1 (PD-L1) expression in this rare subtype9–11.